Le Lézard
Classified in: Health
Subject: PER

Biovica Strengthens Management Team


STOCKHOLM, Dec. 6, 2019 /PRNewswire/ -- Biovica, active in cancer diagnostics, today announced that Henrik Winther was appointed SVP Business Development and will be part of the management team. He most recently comes from the role of SVP Precision Diagnostics at Immunovia.

"Henrik possesses a rare combination of scientific expertise and commercial experience. With his many years of diagnostics background, he brings with him tremendous insight and an extensive network of contacts. Henrik is an important piece of the puzzle in Biovica's continued market expansion," said Anders Rylander, CEO of Biovica.

Winther has previously worked as Global VP of Business Development at the Danish diagnostics company Dako and later as General Manager of the Companion Diagnostic (CDx) Division at Agilent Technologies based in California. Earlier in his career, Winther headed the R&D diagnostic reagents development at Dako. Prior to that he was associate professor in anatomy, physiology and cell biology at the University of Copenhagen. He will start at Biovica on November 18.

"For a decade, Companion Diagnostics i.e. patient stratification for the right individualized treatment has been the focus of the industry. Now, the next very important topic to secure safe and effective treatments within personalized cancer medicine is the monitoring of patient response to therapy," said Winther.

"Biovica is in a strong position with its DiviTum test which provides a unique tool to oncologists that allows for a fast, robust and reliable assessment of patients' response to a given treatment. DiviTum really has a great potential as it is already CE marked, has interesting applications, support from key opinion leaders globally and several excellent clinical study results. The pieces are in place to take Biovica to the next level," he said.

Audiocast
When:     6 December 2019 at 10.00 CET
Where:   https://tv.streamfabriken.com/biovica-international-q2-2019 or
SE: +46850558369 / DK: +4578150107 / UK: +443333009261 / US: +18335268384
Broadcast language: in English

CONTACT:

For more information
Anders Rylander, CEO Biovica
phone: +46 (0)18 444 48 35
email: anders.rylander@biovica.com

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/biovica-international-ab/r/biovica-strengthens-management-team,c2984506

The following files are available for download:

https://mb.cision.com/Main/14910/2984506/1157110.pdf

2019-12-06_Biovica_Press_Release_ENG

https://news.cision.com/biovica-international-ab/i/henrik-winther-bw-s,c2725238

Henrik Winther bw-s

SOURCE Biovica International AB


These press releases may also interest you

at 02:30
PharmaMar (MSE:PHM) and Jazz Pharmaceuticals plc announce that the waiting period under the Hart-Scott-Rodino Antitrust...

at 02:30
FSD Pharma Inc.   (FRA: 0K9A) ("FSD Pharma" or the "Company") today announced that it has appointed Larry Kaiser, MD, FACS to its Board of Directors, effective immediately. Dr. Kaiser will also continue to serve as the Chairman of FSD Pharma's...

at 02:21
Moberg Pharma AB (OMX: MOB) has now completed the expert evaluation of the results from the North American Phase 3-study. The analysis conducted with key opinion leaders (KOLs) has confirmed the validity of the data presented in December 2019 and...

at 02:20
Hansa Biopharma will publish its Year-End report 2019 at 8:00 a.m. CET on February 6, 2020. All interested parties are invited to participate in a telephone conference, which will include a presentation of the interim results and a business update,...

at 02:14
Envirotainer, the global market leader in secure cold chain solutions for air transport of pharmaceuticals, today announced that Eddy Cojulun joined Envirotainer as the new Chief Sales Officer (CSO) in December 2019. In his new role Eddy will report...

at 02:13
Calliditas Therapeutics AB (publ) ("Calliditas") today announced that the EMA Paediatric Committee (PDCO) has adopted a positive opinion on the Paediatric Investigation Plan (PIP) for Nefecon for the treatment of primary IgA nephropathy (IgAN). With...



News published on 6 december 2019 at 02:08 and distributed by: